Regen BioPharma Inc (RGBP) stock
RGBPOTCPharmaceutical PreparationsFiscal year ends September 30Also trades as RGBPP
$0.00+0.00 (+50.00%)
Close on Oct 19, 2026Market cap $92.33KP/E –Yield –
Regen BioPharma total assets
Total assets on the balance sheet at the end of each period.
Regen BioPharma's total assets was $287.59K at Jun 30, 2026. For fiscal 2025 it was $274.63K, up 70.5% from the year before. Over ten years it grew 2.2% a year on average. The highest annual figure on record is $1.21M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $274.63K | +70.5% |
| FY2024 | Sep 30, 2024 | $161.08K | -54.4% |
| FY2023 | Sep 30, 2023 | $353.62K | -36.7% |
| FY2022 | Sep 30, 2022 | $559.00K | -53.9% |
| FY2021 | Sep 30, 2021 | $1.21M | +883.9% |
| FY2020 | Sep 30, 2020 | $123.19K | +24.3% |
| FY2019 | Sep 30, 2019 | $99.09K | -52.6% |
| FY2018 | Sep 30, 2018 | $209.02K | -77.9% |
| FY2017 | Sep 30, 2017 | $944.24K | +195.7% |
| FY2016 | Sep 30, 2016 | $319.36K | +44.9% |
| FY2015 | Sep 30, 2015 | $220.45K | +1969.0% |
| FY2014 | Sep 30, 2014 | $10.66K | -90.8% |
| FY2013 | Sep 30, 2013 | $115.92K | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $287.59K | +46.1% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $260.19K | +53.5% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $237.08K | +23.9% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $274.63K | +70.5% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $196.84K | +15.7% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $169.48K | +20.4% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $191.42K | +20.0% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $161.08K | -54.4% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $170.15K | -40.3% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $140.77K | -65.4% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $159.53K | -61.5% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $353.62K | -36.7% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $285.20K | -58.6% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $406.64K | -35.5% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $414.11K | -43.7% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $559.00K | -53.9% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $689.69K | -51.9% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $630.87K | +254.4% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $735.24K | +388.2% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $1.21M | +883.9% |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $1.43M | +1401.6% |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $178.02K | +86.5% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $150.60K | +267.3% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $123.19K | +24.3% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $95.48K | -16.5% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $95.48K | +117.5% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $41.01K | -77.5% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $99.09K | -52.6% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $114.30K | -79.5% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $43.89K | -94.2% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $182.25K | -84.1% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $209.02K | -77.9% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $558.81K | -42.1% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $757.06K | +26.5% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $1.15M | +62.6% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $944.24K | +195.7% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $965.56K | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $598.50K | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $706.66K | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $319.36K | – |
See a number that looks wrong?